149 related articles for article (PubMed ID: 9779795)
1. Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization.
Schaffer L; Verkhivker GM
Proteins; 1998 Nov; 33(2):295-310. PubMed ID: 9779795
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
Hoog SS; Towler EM; Zhao B; Doyle ML; Debouck C; Abdel-Meguid SS
Biochemistry; 1996 Aug; 35(32):10279-86. PubMed ID: 8756683
[TBL] [Abstract][Full Text] [Related]
3. Exploring the conformational landscapes of HIV protease structural ensembles using principal component analysis.
Hassan S; Srikakulam SK; Chandramohan Y; Thangam M; Muthukumar S; Gayathri Devi PK; Hanna LE
Proteins; 2018 Sep; 86(9):990-1000. PubMed ID: 30051500
[TBL] [Abstract][Full Text] [Related]
4. Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I.
Pawar S; Wang YF; Wong-Sam A; Agniswamy J; Ghosh AK; Harrison RW; Weber IT
Biochem Biophys Res Commun; 2019 Jun; 514(3):974-978. PubMed ID: 31092330
[TBL] [Abstract][Full Text] [Related]
5. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
6. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
7. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
[TBL] [Abstract][Full Text] [Related]
8. A mean field model of ligand-protein interactions: implications for the structural assessment of human immunodeficiency virus type 1 protease complexes and receptor-specific binding.
Verkhivker GM; Rejto PA
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):60-4. PubMed ID: 8552675
[TBL] [Abstract][Full Text] [Related]
9. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins?
Chen YZ; Gu XL; Cao ZW
J Mol Graph Model; 2001; 19(6):560-70. PubMed ID: 11552685
[TBL] [Abstract][Full Text] [Related]
10. Effect of structural stress on the flexibility and adaptability of HIV-1 protease.
Oehme DP; Wilson DJ; Brownlee RT
J Chem Inf Model; 2011 May; 51(5):1064-73. PubMed ID: 21500830
[TBL] [Abstract][Full Text] [Related]
11. Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand.
Lemmon G; Kaufmann K; Meiler J
Chem Biol Drug Des; 2012 Jun; 79(6):888-96. PubMed ID: 22321894
[TBL] [Abstract][Full Text] [Related]
12. Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes.
Verkhivker GM; Rejto PA; Gehlhaar DK; Freer ST
Proteins; 1996 Jul; 25(3):342-53. PubMed ID: 8844869
[TBL] [Abstract][Full Text] [Related]
13. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
[TBL] [Abstract][Full Text] [Related]
14. Efficient molecular docking of NMR structures: application to HIV-1 protease.
Huang SY; Zou X
Protein Sci; 2007 Jan; 16(1):43-51. PubMed ID: 17123961
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
18. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.
Gehlhaar DK; Verkhivker GM; Rejto PA; Sherman CJ; Fogel DB; Fogel LJ; Freer ST
Chem Biol; 1995 May; 2(5):317-24. PubMed ID: 9383433
[TBL] [Abstract][Full Text] [Related]
19. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
20. Structure-based thermodynamic analysis of HIV-1 protease inhibitors.
Bardi JS; Luque I; Freire E
Biochemistry; 1997 Jun; 36(22):6588-96. PubMed ID: 9184138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
